10 completed, 7 recruiting, 3 unknown, 1 withdrawn. 7 Early Phase 1, 7 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Effects of Immunotherapy: new trials by email Literature Review of Effects of Immunotherapy trials Research Report on Effects of Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Gonadotoxic Therapies on Fertility Blood samples for analysis, Sperm samples for analysis, Satisfaction evaluation - Cancer, Fertility Issues | Recruiting | Michael von Wolff | 7000 | 2023-12-01 | 2026-07-30 | |
| A Study of TIL in Advanced Solid Tumors (DFGD) GC203 TIL(gene-edited TIL) or autologous TILs - Advanced Solid Tumor, Tumor Infiltrating Lymphocytes | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 30 | 2023-04-01 | 2025-12-16 |
| A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital) Membrane Bound Cytokine Modified TIL - Advanced Gynecologic Tumors, TIL Engineered With Membrane-Binding Cytokine | Early Phase 1 | Completed | Shanghai Juncell Therapeutics | 26 | 2022-03-10 | 2025-12-11 |
| A Clinical Study on TIL for the Treatment of Advanced Solid Tumors Tumor Infiltrating Lymphocytes - Advanced Solid Tumor, Tumor Infiltrating Lymphocytes | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 50 | 2021-12-10 | 2026-08-05 |
| A Study of GC101 TIL in Advanced Breast Cancer (10hospital) Tumor Infiltrating Lymphocytes (TIL) - Breast Cancer, Treatment Side Effects | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 50 | 2021-11-19 | 2025-12-11 |
| Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC Lenvatinib Oral Product, PD-1 inhibitor, Local treatment - Hepatocellular Carcinoma, Programmed Cell Death 1 | Unknown | Tongji Hospital | 2000 | 2021-11-01 | 2022-06-15 | |
| A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital) Signal Switch Receptor Modified TIL - Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 50 | 2021-09-26 | 2025-12-11 |
| A Study of GC101 TIL in Advanced Melanoma (10hospital) Tumor Infiltrating Lymphocyte - Advanced Melanoma, Tumor Infiltrating Lymphocyte | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 50 | 2021-09-26 | 2025-12-11 |
| A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital) Tumor Infiltrating Lymphocyte - Advanced Liver Cancers, Tumor Infiltrating Lymphocyte | Early Phase 1 | Recruiting | Shanghai Juncell Therapeutics | 50 | 2021-09-26 | 2025-12-11 |
| Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy Sublingual immunotherapy - Effects of Immunotherapy | Phase 3 | Completed | Zagazig University | 64 | 2021-07-27 | 2022-12-20 |
| TIL and Anti-PD1 in Metastatic Melanoma Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event | Phase 1 / Phase 2 | Unknown | Leiden University | 34 | 2018-07-31 | 2023-12-12 |
| Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis Mite extract sublingual immunotherapy (SLIT), Placebo - Atopic Dermatitis, Effects of Immunotherapy | Phase 4 | Completed | Casa Espirita Terra de Ismael | 91 | 2018-05-02 | 2020-08-26 |
| Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma Anti-GD2 CART - Neuroblastoma, Effects of Immunotherapy | Phase 1 | Completed | Zhujiang Hospital | 12 | 2016-01-01 | 2024-03-15 |
| Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Axalimogene filolisbac - Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Completed | Advaxis, Inc. | 12 | 2015-03-04 | 2024-05-20 |
| Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma Stereotactic body radiotherapy (SBRT), Ipilimumab - Melanoma, Effects of Immunotherapy | Phase 1 | Completed | Radiotherapie | 13 | 2015-03-01 | 2017-01-10 |
| Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma Dinutuximab. Immunotherapy - Neuroblastoma, Neoplasm, Residual | Phase 2 | Completed | Fundació Sant Joan de Déu | 24 | 2014-11-26 | 2024-04-22 |
| Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma GeniusVac-Mel4 - Melanoma, Tumor Vaccines | Phase 1 | Completed | University Hospital, Grenoble | 9 | 2013-06-01 | 2025-08-13 |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) - Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 20 | 2011-12-01 | 2012-01-20 |
| Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children Dermatophagoides pteronyssinus, Pharmacotherapy - Allergic Rhinitis, Effects of Immunotherapy | Not applicable | Completed | Beijing Tongren Hospital | 50 | 2009-02-01 | 2011-02-08 |
| Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy Hypersensitivity, Asthma | Completed | Aalborg University | 571 | 2005-11-01 | 2011-12-06 |
Showing 20 of 21. Sign in to see all of them.
Melanoma (3) · Neoplasms (2) · Neuroblastoma (2) · Adenocarcinoma (1) · Asthma (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Dermatitis, Atopic (1) · Drug-Related Side Effects and Adverse Reactions (1) · Eczema (1) · Genital Diseases, Female (1)
Neoplasms (8) · Neoplasms by Histologic Type (7) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Hypersensitivity, Immediate (3) · Immune System Diseases (3) · Neoplasms, Glandular and Epithelial (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Respiratory Tract Diseases (3) · Skin Neoplasms (3)
Sublingual Immunotherapy (2) · Antigens, Dermatophagoides (1) · Blood Specimen Collection (1) · Drug Therapy (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immune Checkpoint Inhibitors (1) · Interleukin-2 (1) · Ipilimumab (1) · Isotretinoin (1) · Nivolumab (1) · Radiosurgery (1) · dinutuximab (1) · liposomal amphotericin B (1) · sargramostim (1)
Shanghai Juncell Therapeutics (7) · Aalborg University (1) · Advaxis, Inc. (1) · Beijing Tongren Hospital (1) · Casa Espirita Terra de Ismael (1) · Fundació Sant Joan de Déu (1) · Jules Bordet Institute (1) · Leiden University (1) · Michael von Wolff (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Radiotherapie (1) · Tongji Hospital (1) · University Hospital, Grenoble (1) · Zagazig University (1) · Zhujiang Hospital (1)
China (10) · Belgium (2) · Brazil (1) · Egypt (1) · France (1) · India (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United States (1)
David Sacks, PhD (1) · Ellen Kapiteijn, Dr. (1) · Jaume Mora, MD (1) · Joel Plumas, PhD (1) · Julie Charles, MD, PhD (1) · Karin D Petersen, PhD (1) · Karla L Arruda, PhD (1) · Lihua Yang, M.D., Ph.D. (1) · Lung-Ji Chang, Ph.D. (1) · Luo Zhang, M.D (1) · Michael von Wolff, Prof. Dr. (1) · Philippe Martiat, MD PhD (1) · Piet Ost, MD, PhD (1) · Qian Zhang (1) · Shyam Sundar, MD (1)